May 2, 2016
Eli Lilly and Company has announced that Taltz® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available in the United States by prescription order through a contracted network of specialty pharmacies. Patient support programs are also offered by Lilly for ensuring that eligible patients have access to Taltz and available resources. U.S. FDA approved Taltz in March 2016 for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for phototherapy or systematic therapy.
“Many people with moderate-to-severe plaque psoriasis are searching for a treatment that will help them achieve high levels of clear skin. With Taltz now available, physicians and patients have a new treatment option that may help patients experience virtually or completely clear skin. Lilly is committed to providing education and resources to help make Taltz accessible to people with moderate-to-severe plaque psoriasis,” said Alex Azar, president, Lilly USA, LLC.
According to Randy Beranek, president of the National Psoriasis Foundation: “The availability of new treatments like Taltz is vitally important for patients with moderate-to-severe plaque psoriasis. The effects of psoriasis can vary among patients and what works for one patient may not work for another. We are happy to see more options available so patients can continue treating this very difficult disease.”